Protagen raises EUR 1 million to expand its protein biochips business unit
Using this new capital Protagen aims to leverage its leading position in protein biochips to create new products and services in the area of biomarkers, both independently and in conjunction with pharmaceutical partners.
Protagen is also working on its own programmes for the development of prototype diagnostics for multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis and Alzheimer's disease. The programme for multiple sclerosis is the most advanced, with a prototype diagnostic for the disease already being tested in large numbers of patients.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.